Azzam Bilal Chamdy
Neng Nana
Nana Muazin
Dwi Wanna
Raul Delapena Setiawan
October 9, 2026 — The European Commission is currently navigating a complex regulatory landscape as it moves toward finalizing new, stringent limits on cereulide—a potent toxin produced by Bacillus cereus—in powdered infant formula. The proposal has drawn significant attention from international trade bodies, most notably the U.S. Dairy Export Council (USDEC), which has joined a chorus of global stakeholders in formally commenting on the draft legislation.
As the European Union seeks to bolster the safety profile of infant nutrition products, the intersection of public health mandates and global trade logistics has created a high-stakes dialogue. The following report outlines the intricacies of the proposed regulation, the industry’s response, and the broader implications for the global dairy supply chain.
The Core Mandate: Understanding Cereulide Risks
Bacillus cereus is a ubiquitous, spore-forming bacterium found in soil and raw agricultural products. While it is a common contaminant, specific strains are capable of producing cereulide, an emetic (vomit-inducing) toxin that is highly resistant to heat and gastrointestinal enzymes.
For the average adult, exposure to B. cereus might result in temporary gastrointestinal distress. However, for infants—whose digestive and immune systems are still in the developmental stages—the presence of this toxin in formula presents a significant health risk. The European Commission’s move to establish specific limits aims to harmonize safety standards across member states and ensure that infant formula—a critical, high-risk food category—meets the highest possible safety benchmarks.
The proposed regulation seeks to shift from a general "absence" or "hygiene indicator" approach to a more rigid, quantifiable maximum limit for cereulide. This transition is intended to provide food safety authorities with a clear, enforceable metric during inspections and product testing.
Chronology of Regulatory Development
The path toward these proposed limits has been years in the making, driven by advancements in analytical chemistry and an evolving understanding of microbial risks.
- 2023–2024: Following reports of localized foodborne incidents linked to B. cereus in dried food products, the European Food Safety Authority (EFSA) accelerated its review of toxin-producing bacteria in powdered infant formula.
- Early 2025: EFSA published its updated scientific opinion, suggesting that current hygiene criteria for B. cereus in infant formula may not sufficiently account for the concentration of cereulide in batches that pass traditional plate-count testing.
- Summer 2026: The European Commission drafted the legislative proposal, initiating a public comment period to allow stakeholders—ranging from health advocacy groups to international trade associations—to weigh in on the technical feasibility of the new limits.
- October 2026: The consultation period concludes, with major global trade players, including the USDEC, submitting detailed feedback regarding the transition timeline and analytical testing methodologies.
Analytical Considerations: The Industry’s Primary Concern
The U.S. Dairy Export Council (USDEC), which represents the interests of American dairy farmers, processors, and exporters, has been a central voice in the feedback process. Their concerns are not necessarily focused on the goal of food safety—which they fully support—but rather on the technical reality of implementation.
The Challenge of Detection
A primary concern raised by the USDEC is the lack of standardized, validated, and rapid analytical methods to detect low levels of cereulide in complex matrices like infant formula. Unlike standard bacterial culture tests, which are relatively affordable and widespread, detecting the cereulide toxin requires sophisticated mass spectrometry.
The Council argues that if the EU imposes a strict limit, it must also recognize that current laboratory capacity to perform these specialized tests is unevenly distributed across the global supply chain. If laboratories in exporting nations cannot perform the tests to the exact specifications required by EU regulators, it could create unnecessary trade barriers, causing shipments to be held at borders despite having no history of contamination.
Transitional Measures
The USDEC also highlighted the necessity for a "grace period." When regulations regarding chemical or microbial contaminants change, supply chains—which often involve products with long shelf lives—cannot shift overnight. The council is advocating for a robust transitional period that allows products already in the distribution pipeline to remain viable, preventing massive food waste and economic loss for dairy cooperatives.
Global Implications: Balancing Safety and Trade
The EU is one of the world’s most influential regulators of food safety. Its decisions frequently become the "gold standard" or the baseline for other nations, including those in the ASEAN and Middle Eastern markets.
The Domino Effect on Global Standards
If the European Commission successfully implements these cereulide limits, it is highly probable that other regulatory bodies—such as those in China, Brazil, or the United Kingdom—will adopt similar measures. This creates a regulatory environment where infant formula manufacturers must design their quality control protocols to satisfy the "strictest common denominator."
For the U.S. dairy industry, which exported significant volumes of whey protein concentrates and dried milk ingredients for infant formula production in 2025, these changes are critical. Failure to align with EU standards could result in a loss of market share, as processors might pivot toward suppliers that can provide certified, low-cereulide ingredients.
Public Health vs. Economic Feasibility
The tension at the heart of this issue is a classic public health dilemma: how to achieve the absolute highest level of safety without imposing costs so high that they force smaller producers out of the market, potentially driving up the cost of infant nutrition for consumers.
Advocates for the regulation argue that the health of the infant is paramount and that technology, while currently expensive, will eventually become standard. The dairy industry, however, emphasizes that regulatory policy should be "science-based and practical," ensuring that the cost of compliance does not inadvertently limit the availability of affordable infant formula.
Supporting Data: Why Cereulide Matters
The scientific consensus on B. cereus is evolving. Historically, food safety programs focused on B. cereus cell counts. However, the discovery that certain strains can produce the emetic toxin even when cell counts are relatively low has rendered traditional testing insufficient.
- Heat Resistance: Cereulide remains stable at 121°C for 90 minutes. This means that standard pasteurization processes used in dairy processing are largely ineffective at neutralizing the toxin if it is already present in the raw ingredient.
- The "Silent" Toxin: Because the toxin is not a living organism, it does not respond to sterilization methods that kill bacteria. It must be prevented at the source—the farm and the processing facility—through rigorous hygiene control.
- Clinical Impact: Research suggests that cereulide acts as a mitochondrial toxin, causing severe vomiting within one to six hours of ingestion. While rare, its impact on a neonate can be debilitating.
Official Responses and Next Steps
While the European Commission has remained measured in its public statements, officials have indicated that the goal is to finalize the regulation by the end of 2026. The comments submitted by the USDEC and other industry groups are currently being reviewed by the European Food Safety Authority and the Commission’s Directorate-General for Health and Food Safety.
A spokesperson for the Commission stated, "Our priority remains the protection of the most vulnerable consumers. We are carefully reviewing the technical feedback provided by international partners to ensure that our proposed limits are both scientifically sound and practically achievable within the global supply chain."
The Road Ahead
Industry experts suggest that the next few months will be critical. If the Commission takes the USDEC’s advice to heart, we may see:
- Phased Implementation: A tiered rollout of the regulations, allowing companies time to upgrade their testing capabilities.
- Harmonized Testing Protocols: A centralized EU-approved list of validated analytical methods, which would provide clarity for international exporters.
- Increased Investment: A surge in R&D spending among dairy ingredient suppliers to develop new on-site, rapid testing kits for B. cereus and cereulide.
As the debate continues, the infant formula sector finds itself at a crossroads. The demand for absolute safety is non-negotiable, but the mechanisms to achieve it are complex. For the U.S. dairy sector and its global counterparts, the next year will be defined by an intense push to modernize testing infrastructure and ensure that the vital supply of infant formula remains uninterrupted, safe, and accessible.
Ultimately, the goal remains universal: ensuring that the most vulnerable members of society are protected from a toxin that, until now, has operated largely in the shadows of food safety regulations. As the EU leads the charge, the rest of the world is watching, waiting to see how the balance between rigorous public health policy and global trade realities will be struck.
